This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

WCLC 2018

World Conference on Lung Cancer 2018

The IASLC World Conference on Lung Cancer presents a unique opportunity for conversation and collaboration in thoracic oncology owing to its diverse multidisciplinary audience. At the meeting, Boehringer Ingelheim will be hosting a symposium as well as presenting a number of publications highlighting our advances in the treatment of lung cancer.

Booth #801
1 Symposium
5 Publications
23rd–26th September 2018
Metro Toronto Convention Centre North Building, Toronto, Canada
Symposium: Overcoming Challenges In Thoracic Malignancies: Expert Insights
symposium_cal
24 September 2018
symposium_cal
18:00pm - 19:30pm
symposium_cal
Room 102, North Building

At this symposium, an international faculty of experts will discuss clinical considerations for sequencing EGFR TKIs, for preventing and managing brain metastases in patients with EGFR mutation-positive NSCLC, and for maximising the potential of TKIs for SqCC of the lung.

Noemi Reguart, MD, PhD

Noemi Reguart, MD, PhD

Medical Oncologist,

Hospital Clinic de Barcelona

Clinical considerations in EGFR mutation-positive NSCLC: the challenge of preventing and managing brain metastases

Barbara Melosky, MD, FRCP(C)

Barbara Melosky, MD, FRCP(C)

Clinical Assistant Professor, Medical Oncology University of British Columbia

Clinical considerations in EGFR mutation–positive NSCLC: does treatment sequence matter?

David R. Gandara, MD

David R. Gandara, MD

Director, Thoracic Oncology Program

University of California, Davis

Maximising the clinical potential of TKIs for patients with squamous NSCLC

Publications

Come and find out more about our emerging data during the scientific programme at WCLC.

Filter by:
Presentation Type
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
Monday 24th September 2018
A Phase IIIb trial of afatinib* in EGFRm+ NSCLC: analyses of outcomes in patients with brain metastases or dose reductions
24th September 2018
9:45–18:00
Exhibit Hall
Presenter(s): Yi-Long Wu
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P1.01-98
Named patient use program for afatinib in advanced NSCLC with progression on prior therapy: experience from Asian centers
24th September 2018
9:45–18:00
Exhibit Hall
Presenter(s): Gee-Chen Chang
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P0.01-11
Impact of afatinib dosing on safety and efficacy real-world in patients with EGFR mutation-positive advanced NSCLC
24th September 2018
9:45–18:00
Exhibit Hall
Presenter(s): Balazs Halmos
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P1.01-28
There are no publications which meet your criteria on this date
Tuesday 25th September
Nintedanib** + pemetrexed/cisplatin in patients with unresectable MPM: Phase III results from the LUME-Meso trial
Tuesday 25th September
09:15-09:25
TBC
Presenter(s): Giorgio Scagliotti
Oral Presentation
Tumour Type(s): MPM
Presentation Number: PL02.09
There are no publications which meet your criteria on this date
Wednesday 26th September
Oncologist Treatment Considerations and Selection in EFGRM+ NSCLC
Wednesday 26th September
09:45-13:30
Exhibit Hall
Presenter(s): Thomas Wehler
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P3.01-108
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

 

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

 

Last updated: August 2018